GlassScriptPhysician profile
Brian A Kopitzki
NPI 1093977985
$6,255.98
in general payments reported to CMS, 2019-2025
40 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $193 · 2021: $585 · 2022: $993 · 2023: $836 · 2024: $1,367 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,626 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,625.56 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.16 | 2019-2025 | |
| Janssen Biotech, INC. | $732.72 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $540.38 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $409.84 | 2019-2025 | |
| Leo Pharma INC. | $350.59 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $306.52 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $279.14 | 2019-2025 | |
| Lilly USA, LLC | $201.22 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $183.58 | 2024-2025 | Nemluvio, Aklief, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $174.25 | 2019-2025 | Cabtreo |
| Pfizer INC. | $163.46 | 2021-2025 | |
| Ucb, INC. | $142.00 | 2019-2025 | Bimzelx |
| Genentech USA, INC. | $140.90 | 2019-2022 | |
| Almirall LLC | $128.10 | 2019-2025 | Seysara, Klisyri |
| Incyte Corporation | $119.27 | 2023-2024 | Opzelura |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $107.47 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $95.38 | 2024-2025 | Hadlima |
| Allergan, INC. | $85.73 | 2019-2022 | |
| Convatec INC. | $76.97 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $72.57 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.32 | 2022-2025 | Cyltezo, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $71.14 | 2023-2025 | Sotyktu |
| Kerecis Limited | $70.58 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen |
| Vyne Pharmaceuticals INC. | $65.79 | 2021 | |
| Mayne Pharma Commercial LLC | $64.65 | 2019-2025 | |
| Amgen INC. | $50.66 | 2023-2025 | Otezla |
| Misonix INC | $47.80 | 2021 | |
| Journey Medical Corporation | $40.29 | 2022-2023 | |
| Prugen, INC. Pharmaceuticals | $37.00 | 2019-2020 | |
| Sandoz INC. | $33.24 | 2019 | |
| Verrica Pharmaceuticals INC. | $31.67 | 2025 | Ycanth |
| Revance Therapeutics, INC. | $29.98 | 2024 | Daxxify |
| Dusa Pharmaceuticals, INC. | $29.92 | 2019 | |
| Organogenesis INC. | $21.32 | 2024 | |
| Dermavant Sciences, INC. | $20.07 | 2023 | Vtama |
| Botanix Sb INC | $19.63 | 2025 | Sofdra |
| Smith+Nephew, INC. | $18.67 | 2021 | |
| Dermira, INC. | $15.00 | 2019 | |
| Mimedx Group, INC. | $14.69 | 2024 | |
| Janssen Scientific Affairs, LLC | $14.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kopitzki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.